Ernexa Therapeutics Inc. (ERNA) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$14.1M, or -$56.00 per diluted share. Operating activities generated -$7.0M of cash, leaving -$7.0M of free cash flow. At fiscal year end, Ernexa Therapeutics held $5.8M in total assets against $3.4M in total liabilities.
Open the full interactive Ernexa Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Ernexa Therapeutics Key Stats
| Share Price | $2.21 |
|---|---|
| Market Cap | $2.6M |
| 52-Week Range | $2.21 – $47.00 |
| Shares Outstanding | 1.2 million (basic, 2026 Q2) |
Ernexa Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.8M | $0 | $0 | $68,000 | $582,000 | — |
| Gross Profit | — | — | — | -$168,000 | $486,000 | — |
| Operating Income | -$6.3M | -$113.6M | -$33.2M | -$21.1M | -$15.7M | -$9.3M |
| Pre-Tax Income | -$4.4M | -$122.3M | -$24.5M | -$21.7M | -$44.5M | -$14.1M |
| Income Tax | -$6,000 | $5,000 | $45,000 | -$3,000 | $30,000 | -$45,000 |
| Net Income | -$4.4M | -$122.3M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| Diluted EPS | -$22650.00 | -$21150.00 | -$3022.50 | -$1530.00 | -$1222.50 | -$56.00 |
Ernexa Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | — | — | $0 | $0 |
| Net Income | -$1.2M | -$1.5M | -$5.5M | -$4.0M |
| Diluted EPS | -$3.75 | -$0.24 | -$6.95 | -$3.40 |
Ernexa Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $777,000 | — | $11.4M | $7.6M | $1.7M | — |
| Current Assets | $1.7M | $18.8M | $13.7M | $9.6M | $2.4M | $3.1M |
| Total Assets | $3.7M | $32.4M | $22.3M | $49.1M | $5.3M | $5.8M |
| Current Liabilities | $2.4M | $3.7M | $7.7M | $6.6M | $2.9M | $3.1M |
| Total Long-Term Debt | $2.0M | — | — | $6.8M | — | — |
| Total Liabilities | $2.9M | $25.9M | $10.2M | $46.9M | $3.6M | $3.4M |
| Shareholders' Equity | $851,000 | $6.5M | $12.1M | $2.2M | $1.7M | $2.4M |
Ernexa Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.9M | -$23.5M | -$21.0M | -$20.4M | -$15.8M | -$7.0M |
| Cash From Investing | $960,000 | -$22.7M | -$47,000 | -$19,000 | -$365,000 | -$37,000 |
| Cash From Financing | $291,000 | $61.6M | $19.6M | $16.6M | $6.3M | $7.2M |
| Free Cash Flow | — | -$23.6M | -$21.3M | -$20.4M | -$16.2M | -$7.0M |
Figures from Ernexa Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ernexa Therapeutics financials page for every line item.
Ernexa Therapeutics Company Profile
| Ticker | ERNA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000748592 |
Frequently Asked Questions
What is Ernexa Therapeutics' annual revenue history?
Ernexa Therapeutics' annual revenue by fiscal year: 2020: $5.8M; 2021: $0; 2022: $0; 2023: $68,000; 2024: $582,000.
What was Ernexa Therapeutics' net income in fiscal 2025?
Ernexa Therapeutics reported net income of -$14.1M for fiscal 2025.
What was Ernexa Therapeutics' earnings per share (EPS) in fiscal 2025?
Ernexa Therapeutics' diluted EPS was -$56.00 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ernexa Therapeutics generate in fiscal 2025?
Ernexa Therapeutics generated -$7.0M of free cash flow in fiscal 2025.
What was Ernexa Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ernexa Therapeutics reported revenue of $0.
How many shares of Ernexa Therapeutics are outstanding?
Ernexa Therapeutics reported a weighted average of 1.2 million basic shares outstanding in 2026 Q2.
What is Ernexa Therapeutics' market cap?
Based on its latest closing price, Ernexa Therapeutics (ERNA) has a market capitalization of about $2.6M.
When does Ernexa Therapeutics' fiscal year end?
Ernexa Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Ernexa Therapeutics headquartered?
Ernexa Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.